As immunotherapies targeting co-stimulatory blockade is becoming a major focus for cancer therapeutics, it is important to understand the spatial and temporal nature of immune gene expression when a patient is under cancer management. This includes longitudinal monitoring of gene profiles before surgery, immediately after surgery and during adjuvant immunotherapy. However, the identification of a biologically interpretable and universally shared (translational) set of immune profiles has proved to be difficult. This problem is also compounded by the fact that the host immune profile is influenced, not only by tumour, but by processes in surgery such as anaesthesia and analgesics (Marik, PE & Flemmer, M. J Trauma Acute Care Surg. 73(4), 808-808 (2012) and Gaudillière, B et al. Sci Transl Med. 6(255), 255ra131 (2014)). The aim is therefore to refine our immune competent mouse models to dissect the distinct components of the myeloid and lymphoid lineage for ovarian, breast and colorectal cancer at all stages of cancer patient management with the intent to decipher the lineage interrelationships among these populations and how it influences disease progression and outcome.|
Our objectives are as follows:
1.1: To refine our immune competent mouse models so that we can distinguish gene expression differences during pre-surgery, post-surgery and adjuvant immunotherapy from the mouse studies and
1.2: Use state-of-art computational approaches combined with MSI data to identify those immune genes that are also relevant in humans
Overview of all packages...